Neurophysiological biomarkers for drug development in schizophrenia.
Schizophrenia represents a pervasive deficit in brain function, leading to hallucinations and delusions, social withdrawal and a decline in cognitive performance. As the underlying genetic and neuronal abnormalities in schizophrenia are largely unknown, it is challenging to measure the severity of its symptoms objectively, or to design and evaluate psychotherapeutic interventions. Recent advances in neurophysiological techniques provide new opportunities to measure abnormal brain functions in patients with schizophrenia and to compare these with drug-induced alterations. Moreover, many of these neurophysiological processes are phylogenetically conserved and can be modelled in preclinical studies, offering unique opportunities for use as translational biomarkers in schizophrenia drug discovery.
Javitt
Daniel C
DC
Nathan Kline Institute for Schizophrenia Research/New York University School of Medicine, 140 Old Orangeburg Road, Orangeburg, New York 10962, USA.
Spencer
Kevin M
KM
Thaker
Gunvant K
GK
Winterer
Georg
G
Hajós
Mihály
M
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001307:Auditory Perception; D001921:Brain / Q000473:pathology / Q000503:physiopathology*; D001931:Brain Mapping; D015195:Drug Design; D006801:Humans; D009482:Neurophysiology / Q000379:methods*; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology*
D014150:Antipsychotic Agents